反义寡核苷酸：治疗策略与细胞内化
Antisense Oligonucleotides: Treatment Strategies and Cellular Internalization.
作者信息
Miller Colton M, Harris Edward N
机构信息
Department of Biochemistry, University of Nebraska - Lincoln, 1901 Vine St. Lincoln NE 68588 USA.
出版信息
RNA Dis. 2016;3(4). doi: 10.14800/rd.1393. Epub 2016 Aug 15.
Abstract
The clinical applicaton of antisense oligonucleotides (ASOs) is becoming more of a reality as several drugs have been approved for the treatment of human disorders and many others are in various phases in development and clinical trials. ASOs are short DNA/RNA oligos which are heavily modified to increase their stability in biological fluids and retain the properties of creating RNA-RNA and DNA-RNA duplexes that knock-down or correct genetic expression. This review outlines several strategies that ASOs utilize for the treatment of various congenital diseases and syndromes that develop with aging. In addition, we discuss some of the mechanisms for specific non-targeted ASO internalization within cells.
摘要
随着几种药物已被批准用于治疗人类疾病，并且许多其他药物正处于不同的研发和临床试验阶段，反义寡核苷酸（ASO）的临床应用正日益成为现实。ASO是短的DNA/RNA寡核苷酸，经过大量修饰以提高其在生物体液中的稳定性，并保留形成可敲低或纠正基因表达的RNA-RNA和DNA-RNA双链体的特性。本综述概述了ASO用于治疗各种先天性疾病和随年龄增长而出现的综合征的几种策略。此外，我们还讨论了细胞内特定非靶向ASO内化的一些机制。
相似文献
1
Antisense Oligonucleotides: Treatment Strategies and Cellular Internalization.
RNA Dis. 2016;3(4). doi: 10.14800/rd.1393. Epub 2016 Aug 15.
2
Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver.
Nucleic Acids Res. 2016 Apr 7;44(6):2782-94. doi: 10.1093/nar/gkw112. Epub 2016 Feb 22.
3
Endosomal Escape of Antisense Oligonucleotides Internalized by Stabilin Receptors Is Regulated by Rab5C and EEA1 During Endosomal Maturation.
Nucleic Acid Ther. 2018 Apr;28(2):86-96. doi: 10.1089/nat.2017.0694. Epub 2018 Feb 13.
4
Chloroquine and cytosolic galectins affect endosomal escape of antisense oligonucleotides after Stabilin-mediated endocytosis.
Mol Ther Nucleic Acids. 2023 Jul 19;33:430-443. doi: 10.1016/j.omtn.2023.07.019. eCollection 2023 Sep 12.
5
Phosphorothioate Antisense Oligonucleotides Bind P-Body Proteins and Mediate P-Body Assembly.
Nucleic Acid Ther. 2019 Dec;29(6):343-358. doi: 10.1089/nat.2019.0806. Epub 2019 Aug 20.
6
Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides.
Nucleic Acids Res. 2018 Apr 20;46(7):3579-3594. doi: 10.1093/nar/gky145.
7
Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides.
Nucleic Acids Res. 2017 May 19;45(9):5309-5322. doi: 10.1093/nar/gkx231.
8
Joining forces to develop individualized antisense oligonucleotides for patients with brain or eye diseases: the example of the Dutch Center for RNA Therapeutics.
Ther Adv Rare Dis. 2024 Sep 23;5:26330040241273465. doi: 10.1177/26330040241273465. eCollection 2024 Jan-Dec.
9
Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides.
Nucleic Acids Res. 2016 Sep 6;44(15):7314-30. doi: 10.1093/nar/gkw595. Epub 2016 Jul 4.
10
Hsc70 Facilitates Mannose-6-Phosphate Receptor-Mediated Intracellular Trafficking and Enhances Endosomal Release of Phosphorothioate-Modified Antisense Oligonucleotides.
Nucleic Acid Ther. 2021 Aug;31(4):284-297. doi: 10.1089/nat.2020.0920. Epub 2021 Feb 9.
引用本文的文献
1
Skeletal muscle effects of antisense oligonucleotides targeting glycogen synthase 1 in a mouse model of Pompe disease.
Clin Transl Med. 2025 Apr;15(4):e70314. doi: 10.1002/ctm2.70314.
2
Evolution of antisense oligonucleotides: navigating nucleic acid chemistry and delivery challenges.
Expert Opin Drug Discov. 2025 Jan;20(1):63-80. doi: 10.1080/17460441.2024.2440095. Epub 2024 Dec 17.
3
The Coming Age of Antisense Oligos for the Treatment of Hepatic Ischemia/Reperfusion (IRI) and Other Liver Disorders: Role of Oxidative Stress and Potential Antioxidant Effect.
Antioxidants (Basel). 2024 May 31;13(6):678. doi: 10.3390/antiox13060678.
4
Antisense and Functional Nucleic Acids in Rational Drug Development.
Antibiotics (Basel). 2024 Feb 27;13(3):221. doi: 10.3390/antibiotics13030221.
5
Expression of the Pro-Fibrotic Marker Periostin in a Mouse Model of Duchenne Muscular Dystrophy.
Biomedicines. 2024 Jan 18;12(1):216. doi: 10.3390/biomedicines12010216.
6
A DNA/RNA heteroduplex oligonucleotide coupling asparagine depletion restricts FGFR2 fusion-driven intrahepatic cholangiocarcinoma.
Mol Ther Nucleic Acids. 2023 Oct 5;34:102047. doi: 10.1016/j.omtn.2023.102047. eCollection 2023 Dec 12.
7
Potential of Antisense on Proliferation Abatement.
Iran J Parasitol. 2022 Oct-Dec;17(4):525-534. doi: 10.18502/ijpa.v17i4.11280.
8
Simultaneous Targeting of Multiple oncomiRs with Phosphorothioate or PNA-Based Anti-miRs in Lymphoma Cell Lines.
Pharm Res. 2022 Nov;39(11):2709-2720. doi: 10.1007/s11095-022-03383-y. Epub 2022 Sep 7.
9
Application of Artificial Intelligence in Discovery and Development of Anticancer and Antidiabetic Therapeutic Agents.
Evid Based Complement Alternat Med. 2022 Apr 25;2022:6201067. doi: 10.1155/2022/6201067. eCollection 2022.
10
Neurodegenerative diseases associated with non-coding CGG tandem repeat expansions.
Nat Rev Neurol. 2022 Mar;18(3):145-157. doi: 10.1038/s41582-021-00612-7. Epub 2022 Jan 12.
本文引用的文献
1
Current and emerging treatment options for spinal muscular atrophy.
Degener Neurol Neuromuscul Dis. 2015 Jul 17;5:75-81. doi: 10.2147/DNND.S48420. eCollection 2015.
2
Drug pipeline: 1Q16.
Nat Biotechnol. 2016 May 6;34(5):457. doi: 10.1038/nbt.3571.
3
Pharmacokinetic and Pharmacodynamic Investigations of ION-353382, a Model Antisense Oligonucleotide: Using Alpha-2-Macroglobulin and Murinoglobulin Double-Knockout Mice.
Nucleic Acid Ther. 2016 Aug;26(4):223-35. doi: 10.1089/nat.2016.0607. Epub 2016 Mar 31.
4
Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver.
Nucleic Acids Res. 2016 Apr 7;44(6):2782-94. doi: 10.1093/nar/gkw112. Epub 2016 Feb 22.
5
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.
Lancet. 2015 Oct 10;386(10002):1472-83. doi: 10.1016/S0140-6736(15)61252-1. Epub 2015 Jul 22.
6
Factor XI antisense oligonucleotide for prevention of venous thrombosis.
N Engl J Med. 2015 Jan 15;372(3):232-40. doi: 10.1056/NEJMoa1405760. Epub 2014 Dec 7.
7
Phosphorothioates, essential components of therapeutic oligonucleotides.
Nucleic Acid Ther. 2014 Dec;24(6):374-87. doi: 10.1089/nat.2014.0506.
8
Familial hypercholesterolemia: A review.
Ann Pediatr Cardiol. 2014 May;7(2):107-17. doi: 10.4103/0974-2069.132478.
9
Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits.
Blood. 2014 Mar 27;123(13):2102-7. doi: 10.1182/blood-2013-12-540872. Epub 2014 Feb 5.
10
Preventing early cardiovascular death in patients with familial hypercholesterolemia.
J Am Osteopath Assoc. 2014 Feb;114(2):99-108. doi: 10.7556/jaoa.2014.023.
Zotero 插件